Immunohistochemical characteristics of Breast Cancer patients with the comparative study of BRCA1, ER, PR, BCL2, P53 and Ki-67 immunohistochemical markers: A population based study.

  • Manisha Sharma Sri Guru Ram Das Institute of Medical Sciences and Research
  • Menka Khanna
  • Mridu Manjari
  • Manas Madan
  • Taranveer Singh
  • Tania Garg
Keywords: breast carcinoma, immunohistochemistry, BRCA1, ER, PR, Ki-67

Abstract

Background: To correlate clinicopathological and immunohistochemical profile of BRCA1 positive and non BRCA1 breast cancer patients with ER, PR, BCL2, P53 and Ki-67 to gain more insight into biological characterstics of breast cancer to emphasise the need of genetic testing for BRCA1 in blood relatives of patients with BRCA1 mutation.Methods: The study was conducted in 70 randomly selected cases of breast carcinomas received in the Department of Pathology, SGRDIMSR, Amritsar. Clinical History was taken as per proforma and formalin fixed paraffin embedded tissue was studied for histopathological typing and grading after staining with haematoxylin-eosin. All cases were subjected to immunohistochemistry for BRCA1, ER, PR, P53, BCL2 and Ki-67 expression.Results: Grade II Tumors constituted the maximum (67%). The most common age group was 41-60 years (62%). BRCA1 positivity was seen in 27/70 cases (38%). BRCA1 positive cases tend to present at higher stage than BRCA1 negative cases showing significantly greater tumor size (p< 0.001) and lymph node involvement (p =0.001). Similarly BRCA1 positivity was associated with poor prognostic factors significantly as with high grade of tumor (p=0.015), hormonal receptors negativity (81.5% vs 18.5%, p <0.001) and high profilerative index (71% vs 29%, p<0.007), BRCA1 related cases had significantly high P53 positivity (67% vs 33%, p<0.008) and lower BCL2 expression (78% vs 2.2%, p <0.005)Conclusion: Our study proves that BRCA1 positive tumors have a higher grade and are associated with poor clinicopathological and immunohistochemical prognostic markers. Further studies are needed to justify more aggressive treatment in BRCA1 positive cases.

Author Biography

Manisha Sharma, Sri Guru Ram Das Institute of Medical Sciences and Research
Associate Professor, Department of Pathology

References

1) Szabo CI, King MC. Population genetics of BRCA1 and BRCA2. Am J Hum Genet. 1997;60:1013–20.
2) Clays-Tagoe BNL, Yarney J, Kenu E, Amanhayian ONAK, Enchill E, Obeng I. Profile of cancer patients seen at Korle Bu teaching hospital in Ghana (A cancer registry review). BMC Research Notes. 2014;7:577.
3) Lakhani SR, Gusterson BA, Jacquemier J, et al. The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res. 2000;6:782–9.
4) Phillips KA. Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers. J. Clin. Oncol. 2000;18:107–12.
5) Nofech-Mozes S, Vella ET, Dhesy- Thind S, Hagerty KL, Mangu PB, Temin S. Systemic review on hormone receptor testing in breast cancer. Applied Immunohistochem Mol Morphol. 2012;20(3)214-63.
6) Prabhu JS, Korimarla A, Desai K, Alexander A, Raghvan R, Anupma CE. A majority of low (1-10%) ER positive breast cancers behave like hormone receptor negative tumors. Journal of Cancer.2014;5(2)156-65.
7) Valles PA, Cebollada MM, Vazquez NE, Gracia JA, Diana FE. The usefulness of antibodies to the BRCA1 protein in detecting the mutated BRCA1 gene. An immunohistochemical study. J Clin Pathol 2001;54:476-80.
8) Swisher EM, Gonzalez RM, Taniguchi T. Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas. Mol Cancer 2009;8:48.
9) Jaramillo VI, Press MF, Ricker CN, Dabeau L, Mai PL, Weitzel JN. Pathological characteristics of BRCA- associated breast cancer in Hispanics. Breast Cancer Res Treat. 2011;130(1):281-9.
10) Shetty P. India faces growing breast cancer epidemic. Lancet. 2012;379:992-3.
11) Palacios J, Honrado E, Osorio A, et al. Immunohistochemical Characteristics Defined by Tissue Microarray of Hereditary Breast Cancer Not Attributable to BRCA1 or BRCA2 Mutations: Differences from Breast Carcinomas Arising in BRCA1 and BRCA2 Mutation Carriers. Clin Cancer Res. 2003;9:606–14.
12) Atchley DP, Albarracian CT, Lopez A, Valero V, Amos CL, Gonzalez-Angulo AM. Clinical and Pathologic Characteristics of Patients with BRCA Positive and BRCA-Negative Breast Cancer. J Clin Oncol. 2008;26(2):4282-8.
13) Karp SE, Tonin PN, Begin LR. Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women. Cancer. 1997;80:435-41.
14) Johannsson OT, Idvall L, Anderson C. Tumor biological features of BRCA1 induced breast and ovarian cancer. Eur J Cancer. 1997;33:362-71.
15) Vaziri SA, Krumroy LM, Elson P, et al. Breast tumor immunophenotype of BRCA1- mutation carriers is influenced by age at diagnosis. Clin. Cancer Res. 2001;7:1937–45.
16) Lakhani SR, Van De Vijver MJ, Jacquemier J, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and P53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol. 2002;4(3):2310–18.
17) Armes JE, Trute L, White D, Southey MC, Hammet F, Tesoriero A. Distinct molecular pathogenesis of early-onset breast cancers in BRCA1 and BRCA 2 mutation carriers: a population-based study. Cancer Res. 1999;59:2011-7.
18) Musolino A, Michiara M, Bella MA, et al. Molecular profile and clinical variables in BRCA1-positive breast cancers. A population-based study. Tumori. 2005;91(6):505-12.
19) Grushko TA, Blackwood MA, Schumm PL, et al. Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers. Cancer Res. 2002;62:1481–8.
20) Lakhani SR, Jacquemier J, Sloane JP, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl. Cancer Inst. (Bethesda). 1998;90:1138–45.
21) Robson M, Gilewski T, Haas B, Levin D, Borgen P, Rajan P. BRCA-associated breast cancer in young women. J Clin Oncol. 1998;16:1642-9.
22) Ford D, Easton DF, Stratton M. Genetic heterogeneity and penetrance analysis of the BRCA1 BRCA2 genes in breast cancer families: The Breast Cancer Linkage Consortium. Am J Hum Jenet. 1998;62:676-89.
Published
2016-12-12
Section
Original Article

Most read articles by the same author(s)

1 2 > >>